{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T06:58:09Z","timestamp":1783839489098,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009242","name":"Direction generale de l'offre de soins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004718","name":"Universit\u00e9 de Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.therap.2025.07.003","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:50:24Z","timestamp":1753458624000},"page":"212-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of urine drug screening on opioid agonist treatment maintenance with buprenorphine in primary care in France: A cluster-randomized trial"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-286X","authenticated-orcid":false,"given":"Julie","family":"Dupouy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Authier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Di Patrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gibaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Letrilliart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mayni\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Oustric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.07.003_bib0230","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2025.07.003_bib0235","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.therap.2025.07.003_bib0240","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/17425247.2024.2369756","article-title":"Compared implementation of the long-acting buprenorphine treatment buvidal in four European countries","volume":"21","author":"Rolland","year":"2024","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.therap.2025.07.003_bib0245","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","article-title":"Why buprenorphine is so successful in treating opiate addiction in France","volume":"9","author":"Fatseas","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.therap.2025.07.003_bib0250","first-page":"369","article-title":"Comparison of prescriber evaluations and patient-directed self-reports in office-based practice for buprenorphine treatment of opiate-dependent individuals in France, 2002","volume":"2","author":"Lavie","year":"2008","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.therap.2025.07.003_bib0255","doi-asserted-by":"crossref","first-page":"108891","DOI":"10.1016\/j.jsat.2022.108891","article-title":"Prescribing buprenorphine for opioid use disorder in primary care: a survey of French general practitioners in the Sentinelles network","volume":"143","author":"L\u00e9pine","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.therap.2025.07.003_bib0260","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/JCP.0b013e3181e61923","article-title":"Recent substance intake among patients admitted to acute psychiatric wards: physician's assessment and on-site urine testing compared with comprehensive laboratory analyses","volume":"30","author":"Mordal","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2025.07.003_bib0265","doi-asserted-by":"crossref","first-page":"259","DOI":"10.36076\/ppj.2011\/14\/259","article-title":"Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC\/MS\/MS) of urine drug testing","volume":"14","author":"Manchikanti","year":"2011","journal-title":"Pain Physician"},{"key":"10.1016\/j.therap.2025.07.003_bib0270","first-page":"123","article-title":"Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids?","volume":"9","author":"Manchikanti","year":"2006","journal-title":"Pain Physician"},{"issue":"Suppl. 3","key":"10.1016\/j.therap.2025.07.003_bib0275","first-page":"1","article-title":"Appropriate use of drug testing in clinical addiction medicine","volume":"11","author":"Baxter","year":"2017","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2025.07.003_bib0280","unstructured":"F\u00e9d\u00e9ration fran\u00e7aise d\u2019addictologie. Strat\u00e9gies th\u00e9rapeutiques pour les personnes d\u00e9pendantes des opiac\u00e9s\u00a0: place des traitements de substitution. 2004. https:\/\/www.has-sante.fr\/jcms\/c_272358\/fr\/strategies-therapeutiques-pour-les-personnes-dependantes-des-opiaces-place-des-traitements-de-substitution [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.003_bib0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2515\/therapie\/2013022","article-title":"Opiate substitution treatment's cycles in a five-year followed-up cohort in ambulatory practice","volume":"68","author":"Dupouy","year":"2013","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.07.003_bib0290","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2013.12.009","article-title":"Does urine drug abuse screening help for managing patients? A systematic review","volume":"136","author":"Dupouy","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2025.07.003_bib0295","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0740-5472(03)00066-7","article-title":"Urine testing in methadone maintenance treatment: applications and limitations","volume":"25","author":"Goldstein","year":"2003","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.therap.2025.07.003_bib0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11469-015-9569-7","article-title":"Counselors\u2019 clinical use of definitive drug testing results in their work with substance-use clients: a qualitative study","volume":"14","author":"Rzetelny","year":"2016","journal-title":"Int J Ment Health Addict"},{"key":"10.1016\/j.therap.2025.07.003_bib0305","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/14659890903431603","article-title":"Embarrassing, degrading, or beneficial: patient and staff perspectives on urine drug testing in methadone maintenance treatment","volume":"15","author":"Strike","year":"2010","journal-title":"J Subst Use"},{"key":"10.1016\/j.therap.2025.07.003_bib0310","doi-asserted-by":"crossref","first-page":"b2225","DOI":"10.1136\/bmj.b2225","article-title":"Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study","volume":"338","author":"McCowan","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2025.07.003_bib0315","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/02791072.2020.1824046","article-title":"\u201cThat's no longer tolerated\u201d: policing patients\u2019 use of non-opioid substances in methadone maintenance treatment","volume":"53","author":"Frank","year":"2021","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.therap.2025.07.003_bib0320","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12875-016-0413-3","article-title":"Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients","volume":"17","year":"2016","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.therap.2025.07.003_bib0325","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/fcp.12401","article-title":"Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?","volume":"32","author":"Gentile","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.07.003_bib0330","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.07.003_bib0335","series-title":"Cluster randomised trials","author":"Hayes","year":"2009"},{"key":"10.1016\/j.therap.2025.07.003_bib0340","unstructured":"National Institute on Drug Abuse. Research monograph 73: urine testing for drugs of abuse. https:\/\/sudmed-ms.ru\/Articles\/Urine_Testing.pdf [Accessed 22 July 2025 (131 pp.)]."},{"key":"10.1016\/j.therap.2025.07.003_bib0345","unstructured":"Substance Abuse and Mental Health Services Administration. Mandatory guidelines for federal workplace drug testing programs; 2008. https:\/\/www.govinfo.gov\/app\/details\/FR-2008-11-25\/E8-26726 [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.003_bib0350","unstructured":"Observatoire fran\u00e7ais des drogues et des toxicomanies. Traitements par agonistes opio\u00efdes en France\u00a0\u2013\u00a0Bilan 2024. 2025. https:\/\/www.ofdt.fr\/actualite\/traitements-par-agonistes-opioides-en-france-bilan-2024-2470 [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.003_bib0355","unstructured":"The Health Foundation. Stressed and overworked. 2023. https:\/\/www.health.org.uk\/publications\/reports\/stressed-and-overworked [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.003_bib0360","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000506630","article-title":"Primary care of opioid use disorder: the end of \u201cthe French Model\u201d?","volume":"26","author":"Dupouy","year":"2020","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2025.07.003_bib0365","unstructured":"Data.gov.fr. Open medic\u00a0: base compl\u00e8te sur les d\u00e9penses de m\u00e9dicaments interr\u00e9gimes. 2025. https:\/\/www.data.gouv.fr\/fr\/datasets\/open-medic-base-complete-sur-les-depenses-de-medicaments-interregimes\/ [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.003_bib0370","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.therap.2024.04.002","article-title":"GPs\u2019 practices when prescribing buprenorphine in primary care: a survey among the Sentinelles network","volume":"79","author":"L\u00e9pine","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.07.003_bib0375","doi-asserted-by":"crossref","first-page":"e2331398","DOI":"10.1001\/jamanetworkopen.2023.31398","article-title":"Trends in fatal poisoning among drug users in France from 2011 to 2021: an analysis of the DRAMES register","volume":"6","author":"Revol","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2025.07.003_bib0380","unstructured":"Conseil national de l\u2019Ordre des m\u00e9decins. Atlas de la d\u00e9mographie m\u00e9dicale en France. 2018. https:\/\/www.conseil-national.medecin.fr\/sites\/default\/files\/external-package\/analyse_etude\/hb1htw\/cnom_atlas_2018_0.pdf [Accessed 22 July 2025 (165 pp.)]."},{"key":"10.1016\/j.therap.2025.07.003_bib0385","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3122\/jabfm.2020.01.190233","article-title":"Characteristics of office-based buprenorphine prescribers for medicare patients","volume":"33","author":"Abraham","year":"2020","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.therap.2025.07.003_bib0390","unstructured":"Observatoire fran\u00e7ais des drogues et des toxicomanies. Tableau de bord \u00ab\u00a0Traitement de substitution aux opioides\u00a0\u00bb. 2020. https:\/\/www.ofdt.fr\/sites\/ofdt\/files\/2023-08\/field_media_document-5793-TabTSO200916.pdf [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.003_bib0395","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1186\/s12913-022-08915-1","article-title":"Baseline representativeness of patients in clinics enrolled in the PRimary care Opioid Use Disorders treatment (PROUD) trial: comparison of trial and non-trial clinics in the same health systems","volume":"22","author":"Wartko","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.therap.2025.07.003_bib0400","unstructured":"EMCDDA. European drug report 2021: trends and developments. 2021. https:\/\/www.euda.europa.eu\/publications\/edr\/trends-developments\/2021_en [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.003_bib0405","unstructured":"EMCDDA. 2012 annual report on the state of the drugs problem in Europe. 2012. http:\/\/www.emcdda.europa.eu\/publications\/annual-report\/2012 [Accessed 22 July 2025]."},{"key":"10.1016\/j.therap.2025.07.003_bib0410","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3390\/ijerph18041425","article-title":"What differs between patients under methadone and under buprenorphine for opioid use disorder (OUD) in daily clinical practice in France? A short report","volume":"18","author":"Guillou-Landreat","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2025.07.003_bib0415","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12875-024-02609-9","article-title":"Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings","volume":"25","author":"Hooker","year":"2024","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.therap.2025.07.003_bib0420","doi-asserted-by":"crossref","first-page":"110875","DOI":"10.1016\/j.drugalcdep.2023.110875","article-title":"Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states","volume":"250","author":"Hammerslag","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2025.07.003_bib0425","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000336540","article-title":"On-site drugs of abuse urinary screening tests for the management of opiate-addicted patients: a survey among French general practitioners","volume":"18","author":"Dupouy","year":"2012","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2025.07.003_bib0430","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00216-024-05651-9","article-title":"Quantitative analysis of cannabinoids and metabolites in oral fluid by volumetric absorptive microsampling combined with UHPLC-HRMS","volume":"417","author":"Thiebot","year":"2025","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.therap.2025.07.003_bib0435","doi-asserted-by":"crossref","first-page":"111067","DOI":"10.1016\/j.drugalcdep.2023.111067","article-title":"Association of random and observed urine drug screening with long-term retention in opioid treatment programs","volume":"255","author":"Michener","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2025.07.003_bib0440","doi-asserted-by":"crossref","first-page":"209182","DOI":"10.1016\/j.josat.2023.209182","article-title":"Barriers and facilitators to the involvement of general practitioners in the prescription of buprenorphine","volume":"156","author":"Gimenez","year":"2024","journal-title":"J Subst Use Addict Treat"},{"key":"10.1016\/j.therap.2025.07.003_bib0445","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jsat.2012.11.006","article-title":"Effectiveness of drug tests in outpatients starting opioid substitution therapy","volume":"44","author":"Dupouy","year":"2013","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.therap.2025.07.003_bib0450","doi-asserted-by":"crossref","first-page":"e67981","DOI":"10.2196\/67981","article-title":"Increasing Participation and Completion Rates in Questionnaire surveys of primary care patients: cluster-randomized study","volume":"14","author":"Sebo","year":"2025","journal-title":"Interact J Med Res"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725001052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725001052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T19:50:34Z","timestamp":1779565834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725001052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0040595725001052"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.07.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of urine drug screening on opioid agonist treatment maintenance with buprenorphine in primary care in France: A cluster-randomized trial","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}